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PLINICAL RESEARCH Clinical Trial
ffects of Selective Matrix
etalloproteinase Inhibitor (PG-116800) to Prevent
entricular Remodeling After Myocardial Infarction
esults of the PREMIER (Prevention of
yocardial Infarction Early Remodeling) Trial
ichael P. Hudson, MD, FACC,* Paul W. Armstrong, MD, FACC,† Witold Ruzyllo, MD,‡
ose Brum, MD,§ Lisa Cusmano, MS,§ Piotr Krzeski, MD,§ Robert Lyon, PHD,§
iguel Quinones, MD, FACC, Pierre Theroux, MD, FACC,¶ Diana Sydlowski, MS,*
enry E. Kim, MD, FACC,* Mario J. Garcia, MD, FACC,# Wael A. Jaber, MD, FACC,#
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etroit, Michigan; Edmonton, Alberta, and Montreal, Quebec, Canada; Warsaw, Poland;
incinnati and Cleveland, Ohio; and Houston, Texas
OBJECTIVES We sought to determine whether matrix metalloproteinase (MMP) inhibitor, PG-116800,
reduced left ventricular (LV) remodeling after myocardial infarction (MI).
BACKGROUND PG-116800 is an oral MMP inhibitor with significant antiremodeling effects in animal
models of MI and ischemic heart failure.
METHODS In an international, randomized, double-blind, placebo-controlled study, 253 patients with
first ST-segment elevation MI and ejection fraction between 15% and 40% were enrolled
48  24 h after MI and treated with placebo or PG-116800 for 90 days. Major efficacy end
points were changes in LV volumes as determined by serial echocardiography, and clinical
and safety outcomes were also collected.
RESULTS In total, 203 patients (80%) completed 90 days of treatment and had evaluable baseline
and 90-day echocardiograms. The proportion of patients with anterior MI (78% vs. 81%)
and primary percutaneous coronary intervention (90% vs. 91%) along with baseline LV
ejection fraction (35.5% vs. 36.8%) did not differ between PG-116800-treated and placebo-
treated patients. There was no difference in the change in LV end-diastolic volume index
from days 0 to 90 with PG-116800 versus placebo (5.09  1.45 ml/m2 vs. 5.48  1.41
ml/m2, p 0.42). Changes in LV diastolic volume, LV systolic volume, LV ejection fraction,
sphericity index, plus rates of death or reinfarction were not significantly improved with
PG-116800. PG-116800 was well tolerated; however, there was increased incidence of
arthralgia and joint stiffness without significant increase in overall musculoskeletal adverse
events (21% vs. 15%, p  0.33).
CONCLUSIONS Matrix metalloproteinase inhibition with PG-116800 failed to reduce LV remodeling or
improve clinical outcomes after MI. (J Am Coll Cardiol 2006;48:15–20) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.02.055American College of Cardiology Foundation
s
m
s
p
f
d
d
a
e
a
a
L
t
ieft ventricular (LV) remodeling refers to alterations in LV
hamber size, mass, geometry, and function that result after
yocardial infarction (MI) or pressure/volume overload
1,2). After MI, LV remodeling is mediated by progressive
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resented as Oral Abstract/Late Breaking Sessions of the 54th Annual Scientific
essions of the American College of Cardiology, Orlando, Florida, March 7, 2005.(
Manuscript received September 16, 2005; revised manuscript received January 6,
006, accepted January 9, 2006.tructural changes in cardiac myocytes and the extracellular
atrix (ECM), leading to LV dilation and worsening
ystolic function. Clinically, progressive LV remodeling may
otentiate the development of ventricular arrhythmias, heart
ailure, and subsequent cardiovascular mortality (3–5).
Matrix metalloproteinases (MMPs) are a family of zinc-
ependent proteolytic enzymes that promote ECM degra-
ation (6,7). Enhanced activity of MMPs has been directly
ssociated with cardiac ECM degradation and LV remod-
ling, leading to progressive heart failure in animal models
nd human patients (6–10). Both MMP levels and enzyme
ctivity are increased after MI, suggesting their influence on
V remodeling (11–16). Matrix metalloproteinase inhibi-
ion prevents LV remodeling and improves systolic function
n experimental models of MI (17–21) and heart failure
22–24).
c
o
r
s
o
g
T
m
b
(
r
a
-
c
e
P
i
r
M
t
c
M
T
p
C
s
G
e
w
r
(
f
d
a
s
P
C
c
a
2
n
P
2
s
(

f
a
p
r
p
o
(
m
o
c
t

s
d
m

p
h
P
p
k
c
w
r
a
d
i
a
e
i
t
w
a
d
e
t
f
b
s
s
b
t
w
t
e
d
s
v
1
16 Hudson et al. JACC Vol. 48, No. 1, 2006
Post-MI Matrix Metalloproteinase Inhibition July 4, 2006:15–20Matrix metalloproteinase inhibitors have been evaluated
linically for a number of indications, including cancer,
steoarthritis, and rheumatoid arthritis. These studies have
eported dose- and duration-dependent musculoskeletal
ide effects (arthritis, tendon nodules, decreased joint range
f motion) termed the “musculoskeletal syndrome” that is
enerally reversible on cessation of the study drug (25,26).
he precise etiology and mechanism(s) involved in these
usculoskeletal adverse events are unknown; however,
road-spectrum MMP inhibition and particularly MMP-1
collagenase) inhibition has been hypothesized to be causally
elated.
PG-116800 is an oral MMP inhibitor of the hydroxamic
cid class with high affinity for MMP-2, -3, -8, -9, -13, and
14 and low affinity for MMP-1 and -7, which might produce
ardiac antiremodeling benefits without musculoskeletal side
ffects. We hypothesized that selective MMP inhibition with
G-116800 may attenuate post-MI LV remodeling. Accord-
ngly, we conducted a phase II, international, multicenter,
andomized clinical trial—the PREMIER (Prevention of
yocardial Infarction Early Remodeling) trial—to determine
he effects of PG-116800 on LV remodeling parameters and
linical outcomes.
ETHODS
he PREMIER trial was a randomized, double-blind,
lacebo-controlled trial conducted at 54 centers in Poland,
anada, and the U.S. The study was conducted according to
tandards of International Committee on Harmonization
ood Clinical Practice. The investigational review board at
ach site approved the protocol, and all patients provided
ritten informed consent before enrollment. Patients were
andomly assigned in a 1:1 ratio to receive PG-116800
200-mg oral dose taken twice daily) or matching placebo
or 90 days. Patients were followed up for an additional 90
ays for vital status and adverse events. Randomization was
ccomplished through a telephone interactive voice response
ystem and stratified according to region (North America or
oland) and gender. During the study, safety data from the
ASPI (Cartilage-Sparing Proteinase Inhibitor) study indi-
ated a dose-response increase in musculoskeletal symptoms
mong osteoarthritis patients receiving PG-116800 at dose of
00 mg twice daily (data on file, Procter & Gamble, Cincin-
ati, Ohio). PG-116800 dosing was then adjusted in the
REMIER trial to 200 mg twice daily for 30 days followed by
Abbreviations and Acronyms
ECM  extracellular matrix
LV  left ventricle/ventricular
LVEDVI  left ventricular end-diastolic volume index
MI  myocardial infarction
MMP  matrix metalloproteinase
PCI  percutaneous coronary intervention00 mg once daily for the subsequent 60 days. wEligible patients were ages 18 to 80 years, with ST-
egment elevation MI yielding elevated cardiac markers
creatine kinase-MB isoenzyme, troponin I or troponin T
3 times the upper limit of normal) and LV ejection
raction15% and40% as measured by echocardiography
t the local center 48  24 h after MI. Patients receiving
rimary percutaneous intervention (PCI), fibrinolysis, or no
eperfusion therapy were all eligible. Exclusion criteria were
rior MI, documented or suspected history of heart failure
r depressed LV ejection fraction, severe renal insufficiency
creatinine 2.5 mg/dl), congenital heart disease, autoim-
une or connective tissue disease, chronic substance abuse
r psychiatric illness, hepatic impairment/elevated liver
hemistries (alananine aminotransferase, aspartate amino-
ransferase, gamma-glutamyl-transpeptidase, or bilirubin
1.6 the upper limit of normal), uncontrolled hyperten-
ion (blood pressure 160/100 mm Hg), or severe blood
yscrasias (platelet count100,000; hemoglobin11 g/dl for
en or 10 g/dl for women; or absolute neutrophil count
1,000/l). In addition, patients were excluded if there was
ersistent cardiogenic shock, refractory pulmonary edema, or
emodynamic instability (blood pressure 90/50 mm Hg).
atients receiving cytochrome P450 inducers (carbamazepine,
henobarbital, or phenytoin) or P450 inhibitors (fluvoxamine,
etoconazole, itraconazole, or fluconazole) were also excluded.
Patients meeting the above criteria provided informed
onsent, had baseline blood and urine specimens collected,
ere randomized to either PG-116800 or placebo, and
eceived the study drug at the earliest possible time. Follow-up
ssessments were scheduled at hospital discharge/day 7 and on
ays 14, 30, 45, 60, 75, 90, 120, and 180. These visits
ncluded detailed inquiry of any musculoskeletal symptoms,
ssessment of upper extremity range of motion (goniom-
try), and examination of hand tendon abnormalities. Clin-
cal events were collected and recorded from enrollment
hrough 90 days, whereas vital status and adverse events
ere collected 180 days after enrollment.
Baseline echocardiograms were performed 48  24 h
fter acute MI and sent to the Cleveland Clinic Echocar-
iography Core Laboratory for later LV dimension and
jection fraction quantification. Echocardiograms were ob-
ained serially at days 14, 30, 90, 120, and 180 and
orwarded to the Echocardiography Core Laboratory for
linded interpretation and analysis. Site investigators and
onographers received detailed training to obtain optimal
tandardized echocardiographic images, and perfluorocarbon-
ased contrast agents were used for LV cavity opacification. At
he Echocardiography Core Laboratory, all echocardiograms
ere reviewed by two teams of a sonographer plus cardiologist
o select the optimal image (noncontrast- vs. contrast-
nhanced) for endocardial border definition. The echocar-
iogram with optimal endocardial border definition was
elected as the primary data source for LV dimensions,
olumes, and ejection fraction. Internal review of the first
00 paired echocardiograms (baseline, day 30, and day 90)
as performed and verified no regional variability in echo-
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July 4, 2006:15–20 Post-MI Matrix Metalloproteinase Inhibitionardiography image quality and 10% interobserver vari-
bility in LV dimension measurements.
tudy end points. The primary study end point was the
hange from baseline at 90  5 days in LV end-diastolic
olume index (LVEDVI) as measured by two-
imensional echocardiography. Secondary end points in-
luded LVEDVI change from baseline at 30 days along
ith LV volumes, ejection fraction, and sphericity change at
0 and 90 days, clinical outcomes, mortality, and safety
utcomes. The LV end-diastolic and end-systolic diameters
ere measured at the cardiac base and at midcavity in the
arasternal long axis view, and at the base, midcavity, and
ower third of the LV cavity in the apical two- and
our-chamber views. The LV long axis was measured in the
pical two- and four-chamber views from the apex tip to the
nterior/lateral corner of the mitral annulus. End-diastolic
olume was derived by multiplying the largest long axis (L)
y the largest end-diastolic diameter using the formula:
DV  3.42 (Diametermax  L)  6.44 (27). The LV
jection fraction was calculated using the multiple diameter
ethod, which uses the average of the LV diameters
easured at end-diastole and end-systole from the paraster-
al long axis and apical views together along with an
stimate of fractional long axis shortening (28).
Pertaining to clinical outcomes, severe heart failure was
efined as dyspnea, edema, fatigue symptoms accompanied
y pulmonary edema on chest radiography, need for intra-
enous diuretics, or hospitalization. During initial hospital-
zation, reinfarction was defined as ischemic symptoms plus
ither new ST-segment elevation or 25% re-elevation of
reatine kinase-MB or cardiac troponins from the preceding
alue. After discharge, reinfarction was determined by
schemic symptoms plus elevated creatine kinase-MB/
ardiac troponin greater than the upper limit of normal.
ecurrent ischemia was defined as ischemic symptoms not
eeting reinfarction criteria that were substantiated by new
CG abnormalities or leading to urgent/unplanned cathe-
erization or revascularization. Recorded musculoskeletal
dverse events included the following symptoms or findings:
rthralgia, myalgia, joint stiffness, new tendon thickening or
odule, or 30% decrease in shoulder/elbow range of
otion at two goniometry measurements.
tatistical analysis. Comparability of treatment groups for
aseline characteristics and clinical outcomes were assessed
ith t tests and Fisher exact tests. Day 30 and day 90
chocardiographic changes (treatment efficacy) were com-
ared using t tests for the least-square means and confirmed
y an analysis of variance model with factors for treatment
nd stratification. The benefit of PG-116800 in decreasing
VEDVI versus placebo was expected to be4 ml/m2 with
tandard deviation 10 ml/m2. Allowing for an attrition rate
f 20%, enrollment was targeted at 250 patients to generate
wo treatment groups of 100 patients sufficient to detect the
arget LVEDVI (primary end point) benefit of 4 ml/m2
ith 80% power and two-sided alpha  0.05. Statistical
nalyses were performed using SAS version 8.2 (SAS
r
institute Inc., Cary, North Carolina). One-sided p values
ere reported for the primary end point, whereas two-sided
values are reported otherwise.
An independent Data and Monitoring Committee re-
iewed adverse event reports from study patients and mon-
tored PG-116800 safety data from other clinical trials to
afeguard study subjects and provide guidance to the spon-
or (Procter & Gamble). The PREMIER trial expert panel
unctioned as an advisory committee for the trial and had
omplete access to all echocardiographic and clinical data
fter unblinding. All expert panel members and coauthors
ad a substantial role in trial design, data accrual, and data
nterpretation. Clinical data were collected in an electronic
ata collection form and entered into database managed by
he trial sponsor. All final analyses were conducted by the
ponsor in association with the expert panel.
ESULTS
n total, 128 ST-segment elevation MI patients were
andomized to placebo and 125 patients were randomized to
G-116800. Comparing the PG-116800 and placebo
roups, 99 (79%) versus 108 (84%) completed 90 days of
tudy drug without significant differences in the rates of
tudy drug discontinuation because of voluntary patient
ithdrawals, 11 (9%) versus 4 (3%), or because of adverse
vents, 8 (6%) versus 11 (9%). Among patients receiving
he study drug for the full 90 days, 98% had evaluable
aseline and 90-day echocardiograms for primary end
oint assessment.
able 1. Baseline Characteristics
PG-116800
(n  125)
Placebo
(n  128) p Value
ge (yrs) 59.7  11.7 59.9  10.2 0.93
emale 32 (26%) 34 (34%) 0.89
egion 0.89
Poland 86 (69%) 87 (68%) —
U.S. 16 (13%) 19 (15%) —
Canada 23 (18%) 22 (17%) —
iabetes 18 (14%) 21 (16%) 0.73
ypertension 59 (47%) 58 (45%) 0.80
nterior MI 97 (78%) 104 (81%) 0.53
rimary PCI 113 (90%) 116 (91%) 1.0
ibrinolytic therapy 6 (5%) 7 (5%) 1.0
o reperfusion therapy 6 (5%) 5 (4%) 1.0
eak troponin I (ng/ml) 76  98 77  67 0.93
aseline LVEF (%) 35.4  9.1 36.2  8.2 0.50
ime, onset¡ reperfusion (h) 2.9  6.4 3.2  6.5 0.71
ime, MI¡ study drug (h) 54.4  14.0 53.9  14.6 0.81
ime, PCI¡ study drug (h) 51.7  15.3 50.5  15.2 0.55
ost-MI medications
Beta-blocker 116 (93%) 127 (99%) 0.01
ACEI/ARB 118 (94%) 120 (94%) 1.0
Loop diuretic 39 (31%) 55 (43%) 0.07
Spironolactone 32 (26%) 35 (27%) 0.78
Digoxin 6 (5%) 7 (6%) 1.0
alues are n (%) or mean  SD.
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensineceptor blocker; LVEF  left ventricular ejection fraction; MI  myocardial
nfarction; PCI  percutaneous coronary intervention.
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Post-MI Matrix Metalloproteinase Inhibition July 4, 2006:15–20Patient baseline and clinical characteristics are shown in
able 1. Study groups were well matched overall without
ignificant differences in demographic variables, prognostic
haracteristics, or hospital treatments. The study population
ad mean age of 59.8 10 years, and two-thirds of patients
ere enrolled in Poland. Most patients (79%) had anterior
T-segment elevation MIs and were treated with primary
CI (91%). Baseline LV ejection fraction (36% vs. 37%) and
ime interval from MI to study drug administration (54.4 
4.0 h vs. 53.9  14.6 h) did not differ in the PG-116800
nd placebo groups, respectively. Patients in both treatment
roups had high rates of post-MI beta-blocker and
ngiotensin-converting enzyme inhibitor/angiotensin receptor
locker use exceeding 90%.
Table 2 and Figure 1 present echocardiographic LV
emodeling results including the primary study end point—
LVEDVI—at 90 days. There was no difference in
VEDVI after 30 or 90 days of treatment with PG-116800
ersus placebo. The LV systolic and diastolic volumes,
able 2. Echocardiogaphic LV Remodeling End Points: Day 90
Basel
rimary efficacy, day 90 change from baseline (n  203)
LVEDVI (ml/m2) 63.6
U.S. (n  24) 66.3
Canada (n  31) 63.6
Poland (n  148) 63.1
LV end-diastolic volume (ml) 122.4
LV end-systolic volume (ml) 79.8
LVEF (%) 35.5
Sphericity index (n  181) 0.3
econdary efficacy, day 30 change from baseline (n  207)
LVEDVI (ml/m2) 63.1
U.S. (n  27) 64.9
Canada (n  34) 62.6
Poland (n  146) 62.9
LV end-diastolic volume (ml) 121.4
LV end-systolic volume (ml) 78.9
LVEF (%) 35.7
Sphericity index (n  194) 0.3
The p values compare change in echocardiographic end points between PG-116800
LVEDI  left ventricular end-diastolic volume index; other abbreviations as in TFigure 1. Primary end point/change in left ventricular diasjection fraction, and sphericity index did not differ in the
G-16800 and placebo treatment groups. Although under-
owered, subgroup analysis showed no significant differ-
nces in LVEDVI reduction associated with PG-116800
ose (p  0.27). The 90-day change in LVEDVI did not
iffer significantly between patients receiving placebo (n 
04), original protocol/high-dose PG-116800 (n  40), or
mended protocol/reduced-dose PG-116800 (n 59) (5.48
.41 ml/m2 vs. 7.29  2.28 ml/m2 vs. 3.60  1.88 ml/m2),
espectively.
Table 3 shows 90-day clinical outcomes according to
reatment group. Given the small sample size, there were
ew clinical outcomes. Although not statistically significant,
ates of death and reinfarction were higher in the PG-
16800 treatment group. Table 4 shows adverse events
xperienced at 180 days (90 days during and 90 days after
tudy drug treatment). The proportion of patients with
erious adverse events and the proportion of patients with-
rawn from the study drug because of suspected adverse
Day 30 Change From Baseline
-116800 Placebo
p Value*Change (SE) Baseline Change (SE)
5.09 (1.45) 61.3 5.48 (1.41) 0.42
0.40 (4.23) 51.9 4.37 (4.19) 0.25
0.49 (3.63) 59.6 1.67 (3.76) 0.41
6.84 (1.73) 63.1 6.47 (1.65) 0.56
8.43 (2.73) 117.9 10.35 (2.66) 0.31
0.58 (2.25) 75.2 2.23 (2.20) 0.30
4.85 (0.92) 36.8 4.25 (0.89) 0.32
0.01 (0.01) 0.35 0.01 (0.01) 0.44
5.00 (1.12) 61.1 4.94 (1.10) 0.52
1.10 (3.45) 54.0 2.56 (2.84) 0.21
3.84 (2.75) 59.3 3.29 (2.76) 0.56
6.28 (1.33) 63.0 5.75 (1.33) 0.61
8.47 (2.15) 117.8 8.92 (2.10) 0.44
0.98 (1.76) 74.8 1.23 (1.72) 0.19
5.71 (0.81) 36.8 4.12 (0.79) 0.08
0.01 (0.01) 0.35 0.03 (0.01) 0.10
s placebo.
.and
PG
ine
5
5tolic volume index (LVEDVI), baseline to 90 days.
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July 4, 2006:15–20 Post-MI Matrix Metalloproteinase Inhibitionvents did not differ. Dyspepsia symptoms occurred more
requently in PG-116800–treated patients but were unex-
ectedly absent in the placebo group. Rates of arthralgia and
oint stiffness were higher in the PG-116800 treatment
roup, whereas there was no statistically significant differ-
nce in overall musculoskeletal adverse events (21% vs. 15%,
 0.33) between treatment groups.
ISCUSSION
iven the marked improvement in short-term outcomes
fter contemporary ST-segment elevation MI reperfusion
herapy, recent attempts at further reducing death and
isability have been aimed at limiting infarct size and LV
emodeling. We and others have observed that ventricular
emodeling occurs commonly after MI and leads to pro-
ressive heart failure, exercise intolerance, and other adverse
utcomes.
Both MMP gene expression and activity are increased
fter MI, leading to collagen and elastic fiber degradation,
tructural remodeling of the extracellular matrix, impaired
ollagen formation, and myocardial fibrosis (11–16). Inhi-
ition of MMP prevents progressive ventricular remodeling
n MI and heart failure experimental models (17–24).
G-116800 is a selective MMP inhibitor with a high
ffinity for MMP-2, -3, -8, -9, -11, -13, and -14 and
inimal affinity for MMP-1 and -7. PG-116800 and its
ehydrated salt form PG-530742 had impressive outcomes
n preclinical animal studies, significantly reducing LV
olumes along with infarct zone collagen content in a
ost-MI porcine model (21) and reducing LV volumes plus
mproving ejection fraction in a microembolization, chronic
eart failure canine model (24). Prior studies also suggested
hat MMP-1 inhibition is associated with musculoskeletal
omplaints and that MMP-7 positively contributed to
ound healing. Thus PG-116800 looked particularly prom-
sing because of its MMP selectivity and its expected
avorable efficacy-toxicity profile.
ajor findings. In this first therapeutic human study of
MP inhibition after acute MI, we report that 90 days of
reatment with PG-116800 initiated 48 h after MI had no
eneficial effect on LV remodeling (LV end-diastolic
able 3. Clinical Outcomes, 90 Days
PG-116800
(n  125)
Placebo
(n  128) p Value
eath 4 (3%) 1 (1%) 0.21
einfarction 5 (4%) 4 (3%) 0.50
eath or reinfarction 9 (7%) 5 (4%) 0.17
ecurrent ischemia 3 (1%) 3 (1%) 1.0
evere heart failure 13 (10%) 12 (9%) 0.84
ardiogenic shock 2 (2%) 1 (1%) 0.62
ardiac arrest 4 (2%) 0 (0%) 0.06
ardiac tamponade 0 (0%) 1 (1%) 1.0
ajor arrhythmia 9 (7%) 2 (2%) 0.03
eath, reinfarction, cardiac
arrest, or major arrhythmia
13 (10%) 7 (5%) 0.10olume index) or clinical outcomes. PG-116800 was gen-
mrally well tolerated and produced no significant increase in
verall musculoskeletal adverse outcomes. Based on prior
tudies, 90 days should have provided ample time to observe
change in LVEDVI (29). We did encounter considerable
ndividual variability among the serial LVEDVI measure-
ents; however, the absolute change per group (5 ml/m2)
nd variability (14%) were similar to the prestudy estimates,
iving us adequate statistical power to observe a change. It
s unlikely that a different cardiac imaging modality (i.e.,
ardiac magnetic resonance imaging) or diagnostic assess-
ent of LV remodeling would have affected our results.
chocardiography was chosen to assess LV remodeling
ecause it was readily available in most centers, permitted
fficient screening of potential patients, and had substanti-
ted the benefits of angiotensin-converting enzyme inhibi-
ors and beta-blockers on LV volumes and ejection fractions
n prior post-MI studies (30–32).
tudy limitations. The combined use of contemporary MI
herapies may have diminished any potential therapeutic
fficacy of MMP inhibition in our study patients. Primary
CI, beta-blockers, angiotensin-converting enzyme inhibi-
ors, and statins were used by 90% of patients in both
reatment groups. Because these contemporary therapies
long with aldosterone inhibition (33) prevent LV remod-
ling, it is possible that an additional salutary PG-116800
ffect may have been diminished or gone undetected.
Inadequate PG-116800 dosing also may have affected our
esults. At study onset, we planned to administer 200 mg of
G-116800 twice daily for 90 days. Based on reports of
usculoskeletal adverse events in a parallel trial using
G-116800 for osteoarthritis and subsequent concerns
aised by Health Canada, we amended our protocol, re-
uced PG-116800 cumulative dose by 33%, and completed
he study with PG-116800–treated patients receiving a
osing regimen lacking prior experimental efficacy. It is
ncertain whether more potent MMP inhibition might
revent LV remodeling; conversely our results showed no
ose response relationship between PG-116800 and
able 4. Mortality and Adverse Events, 180 Days
PG-116800
(n  125)
Placebo
(n  128) p Value
eath 4 (3%) 1 (1%) 0.21
AE 38 (30%) 36 (28%) 0.78
ithdrew because of SAE 6 (5%) 7 (5%) 1.0
enal failure 3 (2%) 4 (3%) 1.0
yspepsia/gastrointestinal upset 16 (13%) 0 (0%) 0.01
nxiety 10 (8%) 3 (2%) 0.05
usculoskeletal adverse events* 26 (21%) 19 (15%) 0.33
Arthralgia 17 (14%) 10 (8%) 0.16
Myalgia 3 (2%) 2 (2%) 0.68
Joint stiffness 7 (6%) 0 (0%) 0.01
Decreased range of motion 2 (2%) 4 (3%) 0.68
Tendon disorders† 7 (6%) 3 (2%) 0.21
Extremity nodule 4 (3%) 4 (3%) 1.0
Arthralgia, myalgia, joint stiffness, 30% decrease in shoulder or elbow range of
otion, tendon disorder, or extremity nodule. †Tendon contracture or tendonitis.
SAE  serious adverse events.
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Post-MI Matrix Metalloproteinase Inhibition July 4, 2006:15–20VEDVI change and no diminution of drug efficacy after
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onclusions. Contrary to animal and preclinical data, our
isappointing results cast doubt on whether MMP inhibi-
ion might ameliorate post-MI remodeling. Selective MMP
nhibition with PG-116800 is ineffective for treating this
ondition, yet our current understanding of which MMP(s)
ontribute most to ventricular remodeling is rudimentary.
uture research in post-MI patients is needed to better
dentify the clinical and biologic determinants of LV re-
odeling, to understand the timing and sequence of MMP
ctivation and inhibition, and to identify alternative, more-
pecific MMP targets (34). Additionally, the association
etween MMP inhibition and musculoskeletal adverse
vents needs increased study because our results suggest that
elective sparing of MMP-1 inhibition is not sufficient to
void all MMP musculoskeletal side effects.
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or a list of the participants in the PREMIER trial, please
ee the online version of this article.
